↓ Skip to main content
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (54th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

guideline
1 clinical guideline source

Readers on

mendeley
50 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Article details
Title
A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study
Published in
Gynecologic Oncology, July 2015
DOI 10.1016/j.ygyno.2015.07.018
Pubmed ID
Authors

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 50 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
United States 1 2%
France 1 2%
Unknown 48 96%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Student > Ph. D. Student 8 16%
Researcher 8 16%
Student > Bachelor 6 12%
Other 3 6%
Professor 3 6%
Other 4 8%
Unknown 18 36%
Readers by discipline
Readers by discipline Count As %
Medicine and Dentistry 11 22%
Agricultural and Biological Sciences 6 12%
Biochemistry, Genetics and Molecular Biology 3 6%
Pharmacology, Toxicology and Pharmaceutical Science 2 4%
Nursing and Health Professions 2 4%
Other 4 8%
Unknown 22 44%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 February 2021.
All research outputs
#9,106,650
of 26,889,804 outputs
Outputs from Gynecologic Oncology
#1,915
of 4,912 outputs
Outputs of similar age
#96,500
of 277,177 outputs
Outputs of similar age from Gynecologic Oncology
#21
of 49 outputs
Altmetric has tracked 26,889,804 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,912 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.3. This one is in the 35th percentile – i.e., 35% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 277,177 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 54% of its contemporaries.
We're also able to compare this research output to 49 others from the same source and published within six weeks on either side of this one. This one is in the 46th percentile – i.e., 46% of its contemporaries scored the same or lower than it.